Compare Emerson Electric Co. (EMR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Sana Biotechnology Inc — how do they compare? Emerson Electric Co. trades at $163.25 (market cap $91.69B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Emerson Electric Co. is far larger — about 81.1× Sana Biotechnology Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EMR | SANA | |
|---|---|---|
Market Cap | $91.69B | $1.13B |
Sector | Industrials | Health |
52-Week High | $164.38 | $5.92 |
52-Week Low | $123.30 | $2.68 |
Enterprise Value | $102.77B | $1.05B |
Dividend Yield | 1.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $164.02, up 3.36% with strong technical momentum and bullish analyst sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $1.71 exceeding expectations. Recent acquisition of Glue Inc. enhances AI capabilities in test & measurement, supporting the raised 2026 outlook. Valuation metrics show P/E of 35.97 and P/S of 4.97, while profitability remains solid with 13.83% net margin.
EMR presents a favorable risk-reward profile with consensus price target of $171.33 offering 4.5% upside potential. Strong organic growth and AI integration drive optimism, though elevated valuation and overbought technical indicators warrant caution. The stock's proximity to 52-week highs suggests near-term consolidation may precede further gains based on execution of growth initiatives.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
